Carbohydrates For Injection - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Carbohydrates For Injection
Elham Blouet from Roquette explains the importance of carbohydrates for injection and the challenges in this niche market.

Pharmaceutical Technology Europe
Volume 23, Issue 9

Do you think any further improvements can be made to the production of carbohydrate products for injection?

The production of carbohydrates product for injection is based on well-known technologies such as controlled hydrolysis and purification. Any further improvements could be driven by new sophisticated technologies in purification processes, for instance. In addition, processes may also be influenced by European regulations, which are constantly evolving.

With the new ICH Q11 related to the development and manufacture of drug substances, the "enhanced approach" compared with the "traditional approach", development must be based on risk management and more extensive scientific knowledge in order to select unit operations and process parameters that impact critical quality attributes for evaluation in further studies to establish control strategies. In the “traditional approach”, the set points and operating ranges for process parameters are defined and the control strategies are based on demonstration of reproducibility and compliance to acceptance criteria.

Will new or changing regulations in Europe have any affect on the manufacture of carbohydrate products?

Regulations in Europe are continuously evolving. The adoption of directive of Falsified Medicines was driven by the last events on drug medicinal products manufactured with falsified API’s which reached the market via the legal supply chain (example; heparin case). The aim is to strengthen the control of whole manufacture and distribution system of pharmaceutical ingredients and drug products according to GMP and GDP.

These regulations will affect to a certain extent the development and manufacture of active ingredients. For instance, development and manufacture of drug product based on risk-assessment approaches (ICH Q8, Q9) has been extended to API’s development and manufacture (ICH Q11): conception of quality is definitely connected to safety of patients.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology Europe,
Click here